Clinical practice guideline-inconsistent management of fever and neutropenia in pediatric oncology: A Children's Oncology Group study.

BACKGROUND: The primary objective was to measure the proportion of episodes where care delivery was inconsistent with selected recommendations of a clinical practice guideline (CPG) on fever and neutropenia (FN) management. The influence of site size on CPG-inconsistent care delivery, and association between patient outcomes and CPG-inconsistent care were described. METHODS: This retrospective, multicenter study included patients less than 21 years old with cancer who were at high risk of poor FN outcomes and were previously enrolled to a Children's Oncology Group (COG) study at participating National Cancer Institute Community Oncology Research Program (NCORP) institutions from January 2014 through December 2015. Patients were randomly selected for chart review by participating sites from a COG-generated list. Care delivered in each episode was adjudicated (CPG-consistent or CPG-inconsistent) against each of five selected recommendations. RESULTS: A total of 107 patients from 22 sites, representing 157 FN episodes, were included. The most common CPG-inconsistent care delivered was omission of pulmonary computerized tomography in patients with persistent FN (60.3%). Of 74 episodes where assessment of four (episodes without persistent FN) or five (episodes with persistent FN) recommendations was possible, CPG-inconsistent care was delivered with respect to at least one recommendation in 63 (85%) episodes. Site size was not associated with CPG-inconsistent care delivery. No statistically significant association between CPG-inconsistent care and fever recurrence was observed. CONCLUSIONS: In this cohort of pediatric patients at high risk of poor FN outcomes, CPG-inconsistent care was common. Opportunities to optimize resource stewardship by boosting supportive care CPG implementation are highlighted.

Neuro-Behçet's presentation as cerebral venous thrombosis - A report of two cases and review of the literature.

ABSTRACT: Cerebral venous thrombosis (CVT) is a rare stroke with multiple risk factors. One rare risk factor is Behçet's disease (BD). Out of around 3000 cases at our center in the past 10 years, two cases of BD with CVT were seen. Herein, we report on their clinical symptoms, course, and management. Case 1 was a 18-year-old girl with a history of recurrent skin lesions presenting with encephalopathy syndrome due to CVT, requiring decompression. Despite our best efforts, she developed complications and expired due to sepsis. Case 2 was a 22-year-old male with raised intracranial pressure syndrome and a history of recurrent orogenital ulcers. His evaluation showed retinal vasculitis, papilledema, and bilateral lateral rectus palsy. Both had CVT on neuroimaging and had positivity for human leukocyte antigen-B51. Case 2 responded to the anticoagulation and immunomodulation. Risk factor identification is essential in managing CVT, and planned evaluation (clinical or investigations) plays an important role in identifying rare causes that need specific treatment.

Cyclostationary analysis of uterine EMG measurements for the prediction of preterm birth.

Preterm birth (gestational age < 37 weeks) is a public health concern that causes fetal and maternal mortality and morbidity. When this condition is detected early, suitable treatment can be prescribed to delay labour. Uterine electromyography (uEMG) has gained a lot of attention for detecting preterm births in advance. However, analyzing uEMG is challenging due to the complexities associated with inter and intra-subject variations. This work aims to investigate the applicability of cyclostationary characteristics in uEMG signals for predicting premature delivery. The signals under term and preterm situations are considered from two online datasets. Preprocessing is carried out using a Butterworth bandpass filter, and spectral correlation density function is adapted using fast Fourier transform-based accumulation method (FAM) to compute the cyclostationary variations. The cyclic frequency spectral density (CFSD) and degree of cyclostationarity (DCS) are quantified to assess the existence of cyclostationarity. Features namely, maximum cyclic frequency, bandwidth, mean cyclic frequency (MNCF), and median cyclic frequency (MDCF) are extracted from the cyclostationary spectrum and analyzed statistically. uEMG signals exhibit cyclostationarity property, and these variations are found to distinguish preterm from term conditions. All the four extracted features are noted to decrease from term to preterm conditions. The results indicate that the cyclostationary nature of the signals can provide better characterization of uterine muscle contractions and could be helpful in detecting preterm birth. The proposed method appears to aid in detecting preterm birth, as analysis of uterine contractions under preterm conditions is imperative for timely medical intervention.

Hyperbranched polymers: growing richer in flavours with time.

Hyperbranched polymers (HBPs) have been studied for over three decades now; yet several interesting aspects continue to draw the attention of researchers worldwide. This is because of the simplicity of synthesis, their unique globular structure, and the numerous peripherally located functional groups that can be utilised to impart a variety of attributes, such as core-shell amphiphilicity, Janus amphiphilicity, clickable polymeric scaffolds, multifunctional crosslinkers, etc. Several reviews have been written on HBPs with a focus on synthetic strategies, structural diversity, and their potential applications; in this short feature article, we have taken an alternate approach to highlight some of the unique structural features of HBPs and their influence on the properties of HBPs. We also discuss their versatility and adaptability for the generation of several interesting functional polymeric systems. In the latter half, we focus on the utilisation of HBPs as multifunctional scaffolds, that rely on the numerous peripheral terminal groups. We conclude by drawing a structuro-functional analogy between the range of peripherally functionalised HBPs and other analogous, but more complex, polymeric systems. We believe that this review will serve as a visual sounding board that would encourage the development of several other applications for this class of unique polymers.

Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.

AZD1222 (ChAdOx1 nCoV-19) is a replication-deficient adenoviral vectored coronavirus disease-19 (COVID-19) vaccine that is manufactured as SII-ChAdOx1 nCoV-19 by the Serum Institute of India Pvt Ltd following technology transfer from Oxford University/AstraZeneca. The non-inferiority of SII-ChAdOx1 nCoV-19 with AZD1222 was previously demonstrated in an observer-blind, phase 2/3 immuno-bridging study (trial registration: CTRI/2020/08/027170). In this analysis of immunogenicity and safety data 6 months post first vaccination (Day 180), 1,601 participants were randomized 3:1 to SII-ChAdOx1 nCoV-19 or AZD1222 (immunogenicity/reactogenicity cohort n = 401) and 3:1 to SII-ChAdOx1 nCoV-19 or placebo (safety cohort n = 1,200). Immunogenicity was measured by anti-severe acute respiratory syndrome coronavirus 2 spike (anti-S) binding immunoglobulin G and neutralizing antibody (nAb) titers. A decline in anti-S titers was observed in both vaccine groups, albeit with a greater decline in SII-ChAdOx1 nCoV-19 vaccinees (geometric mean titer [GMT] ratio [95% confidence interval (CI) of SII-ChAdOx1 nCoV-19 to AZD1222]: 0.60 [0.41-0.87]). Consistent similar decreases in nAb titers were observed between vaccine groups (GMT ratio [95% CI]: 0.88 [0.44-1.73]). No cases of severe COVID-19 were reported following vaccination, while one case was observed in the placebo group. No causally related serious adverse events were reported through 180 days. No thromboembolic or autoimmune adverse events of special interest were reported. Collectively, these data illustrate that SII-ChAdOx1 nCoV-19 maintained a high level of immunogenicity 6 months post-vaccination. SII-ChAdOx1 nCoV-19 was safe and well tolerated.